Back to Directory

52North

East of England
Founded 2018
Point-of-care diagnostics and AI triage for cancer patients

52North is a medical technology company developing diagnostics and digital tools for urgent cancer care.

Its lead programme is a point-of-care blood test designed to help chemotherapy patients assess their risk of neutropenic sepsis outside hospital, alongside an AI-supported app for triaging acute oncology symptoms.

The tools are intended to help clinicians identify which patients need urgent care and support timely decisions about further assessment.

BiotechDiagnostics & BiomarkersOncologyAI & Machine Learning
In Vitro DiagnosticsClinical Diagnostics

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Latest News

Deals & Funding29 Sept 2026

52North Raises £3.2m to Transform Urgent Cancer Care

52North has raised £3.2m in a round co-led by Macmillan Cancer Support and Hargreave Hale AIM VCT, with participation from Cedars-Sinai Intellectual Property Company, Cancer Research Horizons, the University of Cambridge, OKG Capital and an Innovate UK grant. The funding will support clinical validation, regulatory progress and UK market introduction of Neutrocheck, its portable blood test for identifying chemotherapy patients at risk of neutropenic sepsis.

Source: 52NorthRead source

Company Notes

AKA / Aliases
52North; 52 North Health